Dan Weiss

FDA Calendar: 2H09 Binary Event Trades

I would advise extreme caution on BIEL. In the first quarter of 2009 alone (January-March) the company nearly doubled its shares outstanding from 266.9 million to 492.2 million with sales at 0.005 per share and I would not be shocked if significant additional shares were issued since then.

FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG

I like APPY here although the full market potential will likely not be reached until the second half of 2010. The firm has developed the first test for appendicitis which will not require a CT scan and is currently pending its first 510k submission to the FDA. Ive spoken with almost a dozen physicians who say if this works it will become the standard of care in emergency rooms where anyone who has abdomen pain will be given this test. Estimates for the global market from Think equity, a respected investment research firm are around $1 billion per year, all for a company with a less then $100 million market cap. Of course, this is a highly speculative name but one where if it hits returns of 12-18x the current price or more is very possible.